New drug extends survival in pancreatic cancer

A clinical trial has shown that taking Daruxonrasib daily can nearly double the survival time for patients with advanced pancreatic cancer, with an average survival of 13.2 months compared to 6.7 months with chemotherapy. The drug works by inhibiting a mutant protein that fuels tumor growth in over 90% of cases, representing an important step even though it does not cure the cancer. The results indicate that patients experience fewer side effects and an improved quality of life, with the potential for this treatment to become a new standard for metastatic pancreatic cancer.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل